TY - JOUR
T1 - PAMAM dendrimer with 4-carbomethoxypyrrolidone - In vitro assessment of neurotoxicity
AU - Janaszewska, Anna
AU - Studzian, Maciej
AU - Petersen, Johannes Fabritius
AU - Ficker, Mario
AU - Christensen, Jørn Bolstad
AU - Klajnert-Maculewicz, Barbara
N1 - Copyright © 2015 Elsevier Inc. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Cytotoxicity of cationic amino-terminated PAMAM dendrimer and modified PAMAM-pyrrolidone dendrimer was compared. LDH assay and cell visualization technique were employed. Mouse embryonic hippocampal cells (mHippoE-18) were used. The experiments were performed in FBS-deprived medium. Pyrrolidone-modification significantly diminished toxicity of PAMAM dendrimer. The absence of FBS did not reveal significant impact on the toxic effect. Results from LDH assay and MTT test were in good consistency. Low cytotoxicity of PAMAM-pyrrolidone dendrimer increases reliability of the results showing a small impact of this dendrimer on cell viability.
AB - Cytotoxicity of cationic amino-terminated PAMAM dendrimer and modified PAMAM-pyrrolidone dendrimer was compared. LDH assay and cell visualization technique were employed. Mouse embryonic hippocampal cells (mHippoE-18) were used. The experiments were performed in FBS-deprived medium. Pyrrolidone-modification significantly diminished toxicity of PAMAM dendrimer. The absence of FBS did not reveal significant impact on the toxic effect. Results from LDH assay and MTT test were in good consistency. Low cytotoxicity of PAMAM-pyrrolidone dendrimer increases reliability of the results showing a small impact of this dendrimer on cell viability.
U2 - 10.1016/j.nano.2014.09.011
DO - 10.1016/j.nano.2014.09.011
M3 - Letter
C2 - 25461280
SN - 1549-9634
VL - 11
SP - 409
EP - 411
JO - Nanomedicine: Nanotechnology, Biology and Medicine
JF - Nanomedicine: Nanotechnology, Biology and Medicine
IS - 2
ER -